Mackie Research raised its price target for Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) to 50 cents from 40 cents, reflecting an amended agreement with Aytu Biosciences (NASDAQ:AYTU) that would move their partnership...
Tag - Acerus Pharma
